The project of CAR-T design and mechanism research applied by Dr. Wang Enxiu, the founder of Kati, was funded by the National Natural Science Foundation of China.
On October 12, the director of the Jiangsu Provincial Department of Biomedicine and the Director of the Biological Examination Office of the State Intellectual Property Office led a research team to Nanjing Kati to conduct special investigations on "standardizing the patent examination of immune cell therapy and promoting the high-quality development of the original pharmaceutical industry". The research team visited Katy Medicine and conducted research discussions with the senior management team.
On October 12, the Nanjing Biomedicine Special Event, jointly sponsored by the Office of the Jiangsu Science and Technology Entrepreneurship Competition Organizing Committee and Jiangsu High-Tech Investment Group Co., Ltd., was held in Nanjing Biomedicine Valley. 15 investment institutions walked into Nanjing Cati Biomedicine Co., Ltd., the winning company of the 8th "Entrepreneurship Jiangsu" Science and Technology Entrepreneurship Competition, for in-depth understanding and inspection.
Wang Enxiu was selected as the “Entrepreneurship and Entrepreneurship Program” in 2020
Dr. Enxiu Wang delivered a speech at the Symposium on Frontier Science and Innovative Therapy of Tumor Immunotherapy
On November 19, the GD2-CART cell therapy clinical research on childhood neuroblastoma was held at the Children’s Hospital of Nanjing Medical University (Nanjing Children’s Hospital). The convening of this conference marked the GD2-CART cell therapy for childhood neuroblastoma. The tumor project clinical research started.
